[HTML][HTML] A cost-effectiveness analysis of nivolumab compared with ipilimumab for the treatment of BRAF wild-type advanced melanoma in Australia
MA Bohensky, K Pasupathi, A Gorelik, H Kim… - Value in Health, 2016 - Elsevier
Purpose The aim of this study was to evaluate the cost-effectiveness of nivolumab versus
ipilimumab for the treatment of previously untreated patients with BRAF-advanced …
ipilimumab for the treatment of previously untreated patients with BRAF-advanced …
A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia.
MA Bohensky, K Pasupathi, A Gorelik… - Value in Health: the …, 2016 - europepmc.org
Purpose The aim of this study was to evaluate the cost-effectiveness of nivolumab versus
ipilimumab for the treatment of previously untreated patients with BRAF-advanced …
ipilimumab for the treatment of previously untreated patients with BRAF-advanced …
A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia
MA Bohensky, K Pasupathi, A Gorelik… - Value in …, 2016 - valueinhealthjournal.com
Purpose The aim of this study was to evaluate the cost-effectiveness of nivolumab versus
ipilimumab for the treatment of previously untreated patients with BRAF-advanced …
ipilimumab for the treatment of previously untreated patients with BRAF-advanced …
A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia
MA Bohensky, K Pasupathi… - Value in health: the …, 2016 - pubmed.ncbi.nlm.nih.gov
Purpose The aim of this study was to evaluate the cost-effectiveness of nivolumab versus
ipilimumab for the treatment of previously untreated patients with BRAF-advanced …
ipilimumab for the treatment of previously untreated patients with BRAF-advanced …
A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia
MA Bohensky, K Pasupathi, A Gorelik, H Kim… - Value in …, 2016 - research.monash.edu
Purpose The aim of this study was to evaluate the cost-effectiveness of nivolumab versus
ipilimumab for the treatment of previously untreated patients with BRAF-advanced …
ipilimumab for the treatment of previously untreated patients with BRAF-advanced …
A cost-effectiveness analysis of nivolumab compared with ipilimumab for the treatment of BRAF wild-type advanced melanoma in Australia
MA Bohensky, K Pasupathi, A Gorelik… - Value in …, 2016 - acuresearchbank.acu.edu.au
Purpose The aim of this study was to evaluate the cost-effectiveness of nivolumab versus
ipilimumab for the treatment of previously untreated patients with BRAF-advanced …
ipilimumab for the treatment of previously untreated patients with BRAF-advanced …
A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia
MA Bohensky, K Pasupathi, A Gorelik, H Kim… - Value in Health, 2016 - infona.pl
The aim of this study was to evaluate the cost-effectiveness of nivolumab versus ipilimumab
for the treatment of previously untreated patients with BRAF-advanced melanoma (BRAF …
for the treatment of previously untreated patients with BRAF-advanced melanoma (BRAF …